Seeking Alpha
24 Jan 2026, 05:40 UTC · 39w ago
Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator
Impact · against what's priced in
Kiniksa is shifting from a survival-risk profile to a growth-stage company with Arcalyst nearing blockbuster status. The primary value driver is now the transition to self-funding operations and the upcoming Phase 2 data for KPL-387 in H2 2026.
- KNSA+0.60
No priced-in read yet
- In context
The company provides clear visibility toward blockbuster status with 2026 revenue guidance of $900–$920 million and establishes a concrete clinical catalyst for KPL-387 in the second half of 2026.
Read from the article alone
